ArticleProtein science : a publication of the Protein Society2025
Second-order allosteric control as a mechanism for compensatory mutations in B-cell translocation gene 2.
Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research progress on BTG2 in non‑tumor diseases (Review).International journal of molecular medicine · 2026Review
- Second-order allosteric control as a mechanism for compensatory mutations in B-cell translocation gene 2.Protein science : a publication of the Protein Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The mechanism underlying the pathogenic impact of mutations within intrinsically disordered regions of proteins remains enigmatic, and the mechanisms behind compensatory responses to these perturbations lie within an even deeper veil of obscurity. This study focuses on the compensatory mechanisms of single nucleotide variants within the disordered C-terminal tail of the BTG2 protein, a crucial regulator in cell cycle control. Here, we develop a novel approach by combining molecular dynamics simulations with time-dependent linear response theory to accurately compute the long-distance coupling dynamics between the tail and the structured domain. Using this approach, we reveal how specific mutations can counteract the functional disruptions caused by a known disease-associated mutation, V141M. Our findings demonstrate that the disordered tail regulates critical binding sites allosterically, and a weakening of this modulation may contribute to disease manifestation. However, compensatory mutations restore lost interactions between the disordered region and binding sites, exerting long-distance dynamic control over both critical binding sites and the mutation site 141M. This secondhand allosteric control could be a general mechanism for compensatory mutations to rescue function. These insights not only illuminate the pathogenic mechanisms at play but also offer a framework for identifying potential therapeutic targets in diseases associated with disordered protein regions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.